ストックスクリーナーアプリを入手
7.83
0.51%
-0.04
アフターアワーズ：
7.83
前日終値:
$7.87
開ける：
$7.92
24時間の取引高:
1.30M
Relative Volume:
1.22
時価総額：
$2.43B
収益：
$2.68B
当期純損益:
$-184.45M
株価収益率:
-11.51
EPS:
-0.6805
ネットキャッシュフロー:
$229.23M
1週間 パフォーマンス:
+1.29%
1か月 パフォーマンス:
-8.53%
6か月 パフォーマンス:
-3.81%
1年 パフォーマンス:
+36.65%
1日の値動き範囲:
$7.735
$7.95
1週間の範囲:
$7.66
$7.95
52週間の値動き範囲:
$5.01
$9.475
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
名前
Amneal Pharmaceuticals Inc
セクター
電話
908-947-3120
住所
400 Crossing Boulevard, 3rd Floor, Bridgewater
AMRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
7.83 | 2.43B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
160.46 | 71.85B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.08 | 45.58B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.58B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.74 | 19.18B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
128.60 | 13.67B | 612.78M | -86.37M | -62.91M | -0.87 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-09-06 | アップグレード | JP Morgan | Underweight → Neutral |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | アップグレード | Goldman | Sell → Buy |
| 2020-12-14 | アップグレード | Barclays | Equal Weight → Overweight |
| 2020-12-14 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-07-27 | 開始されました | Goldman | Sell |
| 2020-05-12 | アップグレード | Guggenheim | Sell → Neutral |
| 2019-12-12 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2019-11-07 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | 開始されました | Barclays | Equal Weight |
| 2019-05-21 | アップグレード | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | 開始されました | SunTrust | Buy |
| 2019-03-08 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | ダウングレード | SunTrust | Buy → Hold |
| 2018-08-13 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | 開始されました | Morgan Stanley | Overweight |
| 2018-06-22 | 開始されました | B. Riley FBR, Inc. | Buy |
すべてを表示
Amneal Pharmaceuticals Inc (AMRX) 最新ニュース
Amneal gains FDA approval for dementia and oncology drugs - MSN
Amneal Pharmaceuticals (AMRX) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Amneal Launches Mesalamine and Receives FDA Approval for Lenalidomide - Pharmacy Practice News
AMRXAmneal Pharmaceuticals Inc Latest Stock News & Market Updates - StockTitan
Amneal Launches Mesalamine And Receives U.S. FDA Approval For Lenalidomide - Marketscreener.com
Amneal Pharmaceuticals Launching Mesalamine, Gets US FDA Approval for Lenalidomide - Marketscreener.com
Amneal introduces ulcerative colitis drug, plans future launch - Investing.com India
Amneal introduces ulcerative colitis drug, plans future launch By Investing.com - Investing.com Nigeria
Double Win for Amneal: Taps Into $147M Market Today, Secures Future Growth with New FDA Approval - StockTitan
Generic Pharmaceuticals Stocks Q3 Teardown: Amneal (NASDAQ:AMRX) Vs The Rest - Yahoo Finance
There's No Escaping Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Muted Revenues - Simply Wall St
32,757 Shares in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Bought by Entropy Technologies LP - MarketBeat
Amneal Pharmaceuticals : Expiration Dates for Certain Lots of Generic Adrenaclick® Epinephrine Injection, USP Auto-Injector Extended to 20 Months - Marketscreener.com
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest Down 18.0% in January - MarketBeat
Stonebridge Financial Group LLC Buys Shares of 36,054 Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Although Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) insiders have sold lately, they have the highest ownership with 51% stake - Yahoo Finance
Amneal Pharmaceuticals Launches FOCINVEZ: A Game-Changer In Ready-To-Use Antiemetic Injectable Formulations... - WhaTech
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Director Gautam Patel Sells 80,000 Shares - MarketBeat
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives $10.00 Consensus Target Price from Brokerages - MarketBeat
China Universal Asset Management Co. Ltd. Purchases Shares of 65,698 Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Drug Cos. Urge Full Fed. Circ. To Hear Teva Orange Book Row - Law360
Will Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report? - MSN
Amneal Pharmaceuticals Director Sells 80,000 Shares - TradingView
Amneal Pharmaceuticals' SWOT analysis: generic drug maker's stock poised for growth - Investing.com Canada
Wall Street Analysts Predict a 27.12% Upside in Amneal (AMRX): Here's What You Should Know - MSN
Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol - Yahoo Finance
Short Interest in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Declines By 6.8% - MarketBeat
Epinephrine Autoinjector Market to Grow by USD 2.44 Billion (2024-2028), Rising Allergy Prevalence Boosts Growth, with AI Powering Market EvolutionTechnavio - The Malaysian Reserve
SG Americas Securities LLC Has $590,000 Stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
Amneal Says US FDA Accepts New-Drug Application for IPX203 to Treat Parkinson's Disease; Shares Rise - Marketscreener.com
Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025 - BioSpace
Amneal Sets Key Q4 2024 Earnings DateMark Your Calendar for Major Pharma Update - StockTitan
Amneal Celebrates FDA Approvals For Generic Namzaric And Afinitor Disperz - News & Insights
Is Teva-Amneal Inhaler Case A Double-Edged Sword For The Generics Industry? - Citeline News & Insights
Amneal Pharmaceuticals (NASDAQ:AMRX) Trading Up 5.2%Time to Buy? - MarketBeat
Premature Ejaculation Treatment Market to Grow by USD 1.53 Billion (2025-2029), Off-Label Drug Efficacy Boosts Revenue, Report with AI-Powered InsightsTechnavio - The Malaysian Reserve
Amneal Pharmaceuticals Gets FDA Approval for Alzheimer's Treatment and Brain Tumor Drug - MarketWatch
Amneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin - BioSpace
Amneal gains FDA approval for dementia and oncology drugs By Investing.com - Investing.com Australia
Amneal gets FDA approval for generic Byetta, resubmits DHE NDA - MSN
Assenagon Asset Management S.A. Decreases Stock Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Assenagon Asset Management S.A. Trims Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest Update - MarketBeat
Hennessy Advisors Inc. Acquires 106,600 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Amneal Is Targeting 70% Of Untapped Biologics In The ‘Golden Era’ Of Biosimilars - Citeline News & Insights
Is Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year? - MSN
Amneal Pharmaceuticals Inc (AMRX) 財務データ
収益
当期純利益
現金流量
EPS
3.23%
3.94%
大文字化:
|
ボリューム (24 時間):